Gold
Immunocore, LLC
- FLASCO
- February 27, 2023
- No Comments
Immunocore, LLC is a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infectious and autoimmune diseases.
AVEO Oncology
- FLASCO
- May 2, 2022
- No Comments
About Us AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in…
Apellis Pharmaceuticals, Inc.
- FLASCO
- January 25, 2021
- No Comments
We Are Apellis We understand that living with a serious disease–like PNH–can pose many challenges and needs that can remain unaddressed. As leaders in developing targeted C3 therapies, we aim to address these needs by leveraging courageous science, creativity, and compassion to develop transformative therapies for a broad range of debilitating diseases that are driven…
Blue Earth Diagnostics, Inc.
- Katrina Williams
- January 8, 2021
- No Comments
Blue Earth Diagnostics, a subsidiary of Bracco Imaging S.p.A., is a recognized leader in the development and commercialization of novel PET radiopharmaceuticals to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by proven experts in nuclear medicine, who have expanded…
Natera
- Katrina Williams
- September 4, 2019
- No Comments
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types…
Stemline Therapeutics
- Katrina Williams
- February 6, 2019
- No Comments
COMPANY OVERVIEW Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics. In December…
Coherus Biosciences
- Katrina Williams
- February 6, 2019
- No Comments
Coherus is led by a team of biotech industry pioneers focused on disrupting the status-quo and driving tangible change in healthcare. Many of our leaders were directly involved in developing, manufacturing, and commercializing blockbuster biologics that elevated biologics from niche to mainstream medicine. Today, the team is unlocking the true potential of this category and…
Rigel Pharmaceuticals
- FLASCO
- September 24, 2018
- No Comments
Rigel Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company focused on discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Rigel’s clinical development programs span multiple disease targets including chronic immune thrombocytopenia, autoimmune hemolytic anemia and others. Rigel’s first FDA approved product…
Servier Pharmaceuticals
- FLASCO
- September 12, 2018
- No Comments
Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier’s global portfolio…
Agios Pharmaceuticals
- FLASCO
- April 12, 2018
- No Comments
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical…
Biotheranostics a Hologic Company
- FLASCO
- May 12, 2016
- No Comments
Biotheranostics, Inc. represents the oncology portfolio within the Diagnostic Solutions division of Hologic, Inc. The CLIA certified, CAP accredited laboratory provides two proprietary, highly differentiated molecular diagnostic tests for breast and metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID, respectively. Breast Cancer Index (BCI) Breast Cancer Index (BCI) is the only genomic test recognized…
AmerisourceBergen
- April 26, 2015
- No Comments
The importance of ONE package. As part of AmerisourceBergen Oncology Supply meticulously distributes chemotherapy, immunotherapy and supportive care products to community oncology practices nationwide from our office and distribution center in Dothan, Alabama. As your trusted supplier and solutions partner, we go beyond the product, delivering the key knowledge that creates opportunities for growth, solutions…
IPSEN BioPharmaceuticals, Inc.
- FLASCO
- March 25, 2015
- No Comments
Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing medicines in three key therapeutic areas – Oncology, Rare Disease and Neuroscience. We are dedicated to providing hope for patients whose lives are challenged by unmet medical needs. Our…
